Elevance Health, Inc. 8-K

What Happened

• Elevance Health, Inc. (ELV) filed an 8‑K reporting the results of its Annual Meeting of Shareholders held on May 13, 2026. A total of 194,441,339 shares of common stock were represented, constituting a quorum. Three director nominees were elected to three‑year terms, the advisory vote on executive compensation (say‑on‑pay) was approved, Ernst & Young LLP was ratified as the independent auditor for 2026, and a shareholder proposal on studying a ban on corporate contributions to partisan 527 groups was not approved. The report is signed by Kathleen S. Kiefer, Chief Governance Officer and Corporate Secretary.

Key Details

• Directors elected (three‑year terms ending 2029):
  • Gail K. Boudreaux: For 177,978,713; Against 1,714,229; Abstain 110,827; Broker non‑votes 14,637,570.
  • Robert L. Dixon, Jr.: For 174,098,489; Against 5,590,793; Abstain 114,487; Broker non‑votes 14,637,570.
  • Deanna D. Strable: For 175,331,822; Against 4,360,980; Abstain 110,967; Broker non‑votes 14,637,570.
• Advisory vote on executive compensation (say‑on‑pay): For 172,363,616; Against 7,240,619; Abstain 199,534; Broker non‑votes 14,637,570 (approved).
• Ratification of independent auditor (Ernst & Young LLP for FY 2026): For 175,183,332; Against 19,141,697; Abstain 116,310 (ratified).
• Shareholder proposal to study impacts of prohibiting corporate contributions to partisan 527 groups: For 15,587,160; Against 162,924,290; Abstain 1,292,319; Broker non‑votes 14,637,570 (not approved).

Why It Matters

• These results confirm board continuity (three directors re‑elected) and governance approval of the company’s executive pay practices (say‑on‑pay passed), which can affect investor confidence and stability of leadership. Ratifying Ernst & Young maintains auditor continuity for fiscal 2026. The rejection of the shareholder proposal means no immediate study or policy change regarding corporate contributions to partisan 527 political groups was adopted.